Role of abemaciclib in the treatment of hormone dependent, HER2 negative metastatic breast cancer

01/2020

Doc. MUDr. Jan Novotný, Ph.D.

Onkologi, Sunderby Sjukhus, Lulea, Švédsko

SUMMARY

Better therapeutic results that are observed in many different tumor types in the last years are primarily caused by the better understanding of principles of tumor growth and tumor progression. When we focus on breast cancer, the knowledge of these crucial events has led to the development new classes of antineoplastic drugs that attack different signaling pathways including mTOR, PI3K, HER2/Neu as well as G1 checkpoint. Until now there are registered three drugs in the letter mentioned group also called CDK4/6 inhibitors - abemaciclib, palbociclib and ribociclib. In this article, we focus on abemaciclib in the context of other two drugs.

Key words

abemaciclib, palbociclib, ribociclib, CDK4/6 inhibitor, breast cancer